Once-Weekly Obesity Treatment 'IN-B00009'
Targeting the Obesity Treatment Market
HK Innoen is entering Phase 3 clinical trials for its obesity treatment.
On May 8, HK Innoen announced that it had received approval from the Ministry of Food and Drug Safety for its domestic Phase 3 clinical trial plan (IND) for 'IN-B00009' (ingredient name: ecnoglutide), which is being developed as an obesity treatment in the GLP-1 receptor agonist class.
This Phase 3 clinical trial will target adult patients with obesity or overweight who do not have diabetes. IN-B00009 or a placebo will be administered as a subcutaneous injection once a week to evaluate efficacy and safety. The trial is designed as a multicenter, randomized, double-blind, placebo-controlled, parallel-group study, with completion targeted for May 2028.
HK Innoen has set the primary endpoints as the percentage change in body weight at week 40 compared to baseline and the proportion of subjects achieving at least 5% weight loss.
IN-B00009 is a new drug in the Glucagon-Like Peptide-1 Receptor Agonists class. In a previous Phase 2 clinical trial conducted in Australia and New Zealand with obese patients, 26 weeks of administration demonstrated safety as well as a statistically significant weight loss effect compared to liraglutide.
Additionally, in a local Phase 3 clinical trial conducted in China with obese patients, IN-B00009 showed superior weight loss effects compared to placebo.
According to the "Obesity Disease Fact Sheet 2024" published by the Korean Society for the Study of Obesity, the prevalence of obesity among all adults in Korea reached 38.4% as of 2022, and has continued to increase steadily over the past 10 years regardless of gender.
As the global population with obesity increases, the development of obesity treatments is also accelerating. The global obesity treatment market was valued at $19.037 billion (approximately KRW 26.5813 trillion) in 2023, and is projected to grow at an average annual rate of 14.4% to reach $37.3671 billion (approximately KRW 52.1457 trillion) by 2028.
An HK Innoen representative stated, "We will focus all our capabilities on ensuring that IN-B00009 can contribute to the treatment of obesity, a global disease."
IN-B00009 is a substance that HK Innoen introduced in 2024 from the Chinese biopharmaceutical company Sciwind Biosciences Co., Ltd. HK Innoen has secured domestic development and commercialization rights for this substance and is developing it as both an obesity treatment and a diabetes treatment.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
